Call us +91 -7376325889/ 7376335889
Mail
Support
Partners
Careers
Knowledge Center
Downloads
Margin Calculator
Equity
F&O
MF
Online Trading
Open an Account
Back Office
Apply IPO
ABOUT US
SERVICES
MARKETS
Equity
Derivatives
Mutual Fund
IPO
PORTFOLIO
OUR RECOMMENDATIONS
CONTACT US
CALCULATORS
ANNUAL INCOME RANGE
BANK MODIFICATION
MENU
×
HOME
SERVICES
MARKETS
PORTFOLIO
OUR RECOMMENDATIONS
ABOUT US
SERVICES
CONTACT US
CALCULATORS
Online Trading
Open an Account
Back Office
Apply IPO
Equity Analysis
Company Profile
Price
Volume
Analysis
Company Profile
News Analysis
Corporate Action
Other Markets
Detailed Quotes
Detailed Quotes
Company Snapshot
Company Background
Board of Directors
Profit & Loss
Balance Sheet
Quarterly Results
Key Financial Ratios
Share Holding Pattern
Directors Report
Score Board
MF Holdings
Name Change
Company News
Peer Comparison
Monthly High / Low
Price Chart
Consolidated Quarters
FII Holding
Simple & CAGR Growth
Deliverable Volumes
Company News
Hikal Ltd
Industry : Pharmaceuticals - Indian - Bulk Drugs
BSE Code
ISIN Demat
Book Value(
)
524735
INE475B01022
97.5874153
NSE Symbol
P/E(TTM)
Mar.Cap(
Cr.)
HIKAL
63.59
4735.98
EPS(TTM)
Face Value(
)
Div & Yield %:
6.04
2
0.31
Back
GEE Ltd - Announcement under Regulation 30 (LODR)-Newspaper Publication
Nov 15,2024
Pursuant to Regulation 30 and 47 read with Schedule III of SEBI (LODR) Regulations 2015 please find enclosed copy of newspaper publication in the following newspapers with respect to unaudited Financial Results for the quarter and half-year ended September 30 2024 approved at the meeting of Board of Directors held on November 14 2024: 1. Business Standard 2. Navakal